Results 11 to 20 of about 42,548 (287)

Gradeability and Reproducibility of Geographic Atrophy Measurement in GATHER-1, a Phase II/III Randomized Interventional Trial

Ophthalmology Science
Objective: To validate GATHER-1 inclusion criteria and the study’s primary anatomic end point by assessing the reproducibility of geographic atrophy (GA) measurements and factors that affect reproducibility.
Angela S. Li, MD, Justin Myers, BS, Sandra S. Stinnett, DrPH, Dilraj S. Grewal, MD, Glenn J. Jaffe, MD   +4 more
doaj   +3 more sources

Clinical Outcomes of Treatment of Geographic Atrophy: A Narrative Review [PDF]

Ophthalmology and Therapy
Rationale In 2023, the U.S. Food and Drug Administration approved pegcetacoplan (SYFOVRE) as the first therapeutic option for geographic atrophy (GA), a previously untreatable condition associated with age-related macular degeneration.
Anne Helene Køllund Nissen, Thomas Lee Torp, Anna Stage Vergmann   +2 more
doaj   +2 more sources

Geographic Atrophy [PDF]

JAMA Ophthalmology, 2014
Geographic atrophy (GA) is the major cause of blind registration in Western communities, although, with few exceptions, it is less common than choroidal neovascular disease. The variation of phenotype implies that age-related macular degeneration (AMD) does not follow the same course from one case to another and that phenotyping may be important before
Alan C, Bird, Rachel L, Phillips, Gregory S, Hageman   +2 more
openaire   +3 more sources

Geographic Atrophy in Age-Related Macular Degeneration

Ophthalmology Science, 2023
Purpose: To examine disease progression in age-related macular degeneration (AMD) at 2 distinct stages, progression to geographic atrophy (GA) versus GA expansion, by comparison of the risk and protective factors at each stage.
Tiarnan D.L. Keenan, BM BCh, PhD
doaj   +1 more source

Geographic atrophy: pathophysiology and current therapeutic strategies

Frontiers in Ophthalmology, 2023
Geographic atrophy (GA) is an advanced stage of age-related macular degeneration (AMD) that leads to gradual and permanent vision loss. GA is characterized by the loss of photoreceptor cells and retinal pigment epithelium (RPE), leading to distinct ...
Kalpana Rajanala, Farokh Dotiwala, Arun Upadhyay   +2 more
doaj   +1 more source

Choroidal Round Hyporeflectivities in Geographic Atrophy. [PDF]

PLoS ONE, 2016
In geographic atrophy (GA), choroidal vessels typically appear on structural optical coherence tomography (OCT) as hyperreflective round areas with highly reflective borders.
Eleonora Corbelli, Riccardo Sacconi, Luigi Antonio De Vitis, Adriano Carnevali, Alessandro Rabiolo, Lea Querques, Francesco Bandello, Giuseppe Querques   +7 more
doaj   +1 more source

Compass Fundus-Guided Perimetry in Geographic Atrophy

Journal of Ophthalmology, 2022
Purpose. To evaluate compass (CMP), a recently introduced device that combines scanning ophthalmoscopy, automated perimetry, and eye tracking, for fundus-guided perimetry (microperimetry) with the purpose of correlating perimetric retinal sensitivity ...
Roberta Farci, Arturo Carta, Paolo Fogagnolo, Luca Mario Rossetti, Maurizio Fossarello   +4 more
doaj   +1 more source

αA crystallin may protect against geographic atrophy-meta-analysis of cataract vs. cataract surgery for geographic atrophy and experimental studies. [PDF]

PLoS ONE, 2012
BACKGROUND: Cataract and geographic atrophy (GA, also called advanced "dry" age-related macular degeneration) are the two major causes of visual impairment in the developed world.
Peng Zhou, Hong-Fei Ye, Yong-Xiang Jiang, Jin Yang, Xiang-Jia Zhu, Xing-Huai Sun, Yi Luo, Guo-Rui Dou, Yu-Sheng Wang, Yi Lu   +9 more
doaj   +1 more source

Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules [PDF]

, 2019
The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called ...
Cerini, Alberto, Greco A., La Cava M, Lambiase A, Limoli PG, Nebbioso M   +5 more
core   +1 more source

Is There a Relationship Between Use of Anti-Vascular Endothelial Growth Factor Agents and Atrophic Changes in Age-Related Macular Degeneration Patients?

Türk Oftalmoloji Dergisi, 2018
Choroidal neovascularization due to age-related macular degeneration (AMD) is currently treated successfully with anti-vascular endothelial growth factor (VEGF) intravitreal agents.
Süleyman Kaynak, Mahmut Kaya, Derya Kaya   +2 more
doaj   +1 more source